A Randomized Controlled, Open-label, Multi-center Study With 16-week Beinaglutide or Dulaglutide Assessing Effects on Glucose Control and Weight Loss in Type 2 Diabetes With Overweight or Obesity.
Latest Information Update: 20 Mar 2023
Price :
$35 *
At a glance
- Drugs Benaglutide (Primary) ; Dulaglutide
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 15 Mar 2023 Planned primary completion date changed from 31 Aug 2022 to 31 Dec 2023.
- 08 Sep 2021 New trial record